Centre Informs Supreme Court of Hospitals' 700% Medicine Markups

In India, on October 12, 2026, the Centre, through the Ministry of Chemicals and Fertilizers, informed the Supreme Court about the "malpractice" of hospitals selling medicines and consumables to patients at exorbitant mark-ups, sometimes exceeding 700% for anti-cancer drugs, and committed to notifying a list of cancer drugs subject to a 30% trade margin cap.

The Centre, via an affidavit filed by the Ministry of Chemicals and Fertilizers, brought to the Supreme Court's attention the significant issue of hospitals exploiting patients' vulnerable position by selling medicines and consumables at excessively high margins, ranging from 170% to over 700% for anti-cancer drugs. This practice stems from hospitals purchasing medicines from manufacturers offering the highest trade margins and then selling them at Maximum Retail Price (MRP). The Centre acknowledged the inherent information and bargaining asymmetry between patients and healthcare providers. In response, it stated its intention to notify a list of cancer drugs with a 30% trade margin cap, which will be periodically updated. This submission was made in the context of a pending Supreme Court case concerning the capping of prices for all medicines and medical consumables.

This development holds substantial legal significance for healthcare providers, pharmaceutical companies, and patients across India. For hospitals, it signals increased scrutiny and potential regulatory intervention regarding their pricing practices for medicines and consumables, which could significantly impact their revenue models. Pharmaceutical manufacturers might face pressure to adjust their trade margin structures. For patients, it offers the prospect of greater affordability and transparency in healthcare costs, particularly for life-saving treatments like cancer therapy. This move reflects a broader governmental effort to address market failures in essential services where consumer vulnerability is high, even in a competitive market. It also highlights the Supreme Court's role in driving policy changes in public interest matters.

This issue primarily falls under drug pricing regulations, consumer protection laws, and competition law in India. The National Pharmaceutical Pricing Authority (NPPA), under the Ministry of Chemicals and Fertilizers, is the primary body responsible for regulating drug prices under the Drugs (Prices Control) Order (DPCO), which derives its powers from the Essential Commodities Act, 1955. The Centre's proposed 30% trade margin cap for cancer drugs indicates a move towards extending price control mechanisms beyond the manufacturer's price to the retail/hospital sale price, addressing the "trade margin" component. The Supreme Court's involvement underscores its power to intervene in matters of public health and consumer welfare, potentially leading to broader policy directives or legislative amendments if the existing framework is deemed insufficient.

Legal practitioners advising hospitals, pharmaceutical companies, and healthcare providers must closely monitor the notification of the 30% trade margin cap for cancer drugs and any subsequent expansions to other medicines or medical consumables. This will necessitate a review of existing pricing strategies, supply chain agreements, and compliance frameworks to avoid regulatory penalties. For consumer law practitioners, this development provides a strong basis for advocating for patient rights regarding transparent and fair pricing in healthcare. Businesses should prepare for potential audits and increased regulatory oversight, and consider proactive adjustments to their pricing and procurement policies to align with anticipated changes.